inflammatory lung diseases Technology Search | ipal – Ihr professioneller Vermarkter von Erfindungen / Patenten

Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases

15.02.2012 | Ref.Nr. 09061

Life Science › Pharma&Biotech

Biphosphonate with a prolonged carbon chain.Background
Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) - the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases.

Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis.

IP Rights
EP Application (08/2009).
PCT Application (08/2010).
A PCT application was filed in August 2010.

Patent Owner
Humboldt-Universität zu Berlin
Rheinisch-Westfälische
Technische Hochschule Aachen (RWTH)

Application Area:

Drug candidates for the treatment of inflammatory lung diseases, cystic fibrosis and atherosclerosis.

Development Stage: Ex vivo

Schlagworte: Acid Sphingomyelinase, athero-sclerosis, bisphosphonate, cystic fibrosis, inflammatory lung diseases, Inhibitor,

Weitere Kategorien: Life Science, Medical Devices, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Pharmaceuticals

Benefits:

Neutral sphingomyelinase is not influenced
First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent
Inhibition of dexamethasone induced apoptosis was proven in vitro
Substances can easily be synthesized in a one-step or two-step procedure
Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate